Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

HPLC Tests in Quality Control under the Market Surveillance Program for Medicinal Products Containing Amlodipine and Valsartan

Author(s): Dessislava Ilieva-Tonova*, Ivanka Pencheva and Assena Serbezova

Volume 18, Issue 5, 2022

Published on: 12 January, 2022

Page: [513 - 519] Pages: 7

DOI: 10.2174/1573412917666210830130029

Price: $65

conference banner
Abstract

Background: Quality is one of the three main characteristics of medicinal products. The quality assurance process is multi-stage: during the manufacturing, quality control is the commitment of the manufacturer, but after medicinal products become part of the distribution and pharmacy network, analytical quality control is carried out within the program for Market Surveillance. There are different approaches in conducting quality control of medicinal products under the Market Surveillance Program.

Aim: The aim of the study is to compare the results obtained under two approaches: individual testing and testing by groups with the same active substance.

Methods: In this study, comparative tests for assay and purity were carried out within two groups of medicinal products from the antihypertensive group containing Amlodipine besilate and Valsartan. Analyses were performed in accordance with the available pharmacopoeial monographs, as well as those from literature sources.

Results: The results from the assay tests show a significant difference in the same product tested. Analytical methods for the determination of impurities also show different results when analyzing the same medicinal product.

Conclusion: Considering the performed analytical tests, the obtained results can be used to make several conclusions and suggestions concerning the optimisation of the Annual Market Surveillance Program.

Keywords: Quality control, market surveillance program, amlodipine, valsartan, assay, purity.

« Previous Next »
[1]
Little, W.; McGivern, R. Management science for health, part II In: Introduction to sociology – 1st canadian edition; William Little, Ed.; Pressbooks: Amsterdam, 2012; chapter 19.
[2]
Tsvetanova, Y. Features of internal audit in pharmaceutical industry. Pharmacia, 2014, 61(2), 30-34.
[3]
Guidelines on good distribution practice of medicinal products for human use. 2013. C68/01.
[4]
European directorate for the quality of medicines and health care, market surveillance studies. Available from: https://www.edqm.eu/en/market-surveillance-studies-48.html
[5]
SG. Law on medicinal products in human medicine. April, 2007, 13, 31.
[6]
Executive Agency for Medicines. Planning and monitoring of the national market. 2019. SOP 0008-3.
[7]
General European OMCL Network (GEON). Risk analysis model for targeting market surveillance by OMCLs. General document, PA/PH/OMCL, 2020, 80(6), 3-9.
[8]
Ilieva-Tonova, D.; Stoimenova, A.; Pencheva, I. Market surveillance and control of medicinal products in Bulgaria 2009 – 2015. Sci. Technol., 2016, 6(1), 366-373.
[9]
WHO. Guidelines on the conduct of surveys of the quality of medicines. 2015.
[10]
Kumar, M.; Bhatia, R.; Rawal, R.K. Applications of various analytical techniques in quality control of pharmaceutical excipients. J. Pharm. Biomed. Anal., 2018, 157, 122-136.
[http://dx.doi.org/10.1016/j.jpba.2018.05.023] [PMID: 29787965]
[11]
Amlodipine besilate. European pharmacopoeia, 9.1; 2016, 8, 1491.
[12]
Amlodipine besylate tablets. USP41 – NF 36, 2017, 263-264.
[13]
Dinda, S. C.; Desireddy, R.B.; Kumar, P. J.; Chand, A. S.; Rao, P. S.; Kumar, B. A. Development and validation of RP-HPLC method for quantitative analysis of Amlodipine besilate in pure and Pharmaceutical formulations. Research J. Pharm. And Tech., 2013, 6(2)
[14]
Valsartan tablets. USP41 – NF 36, 2017, 4278-4279.
[15]
Valsartan. European pharmacopoeia, 2017(9.1), 2423.
[16]
Ghanty, S.; Das, R.; Maiti, S.; Sen, K.K. RP-HPLC methods for estimation of valsartan in solid oral dosage forms. J. Pharm. Sci., 2014, 3(2), 88-91.
[17]
Paladugo, A.N.D.; Rao, G.D.; Satyanarayana, B.; Poloju, D. Development and validation of RP-HPLC method for quantification of valsartanand its pharmaceutical formulations. Int. J. Drug Devel. Res., 2013, 5(3), 199-205.

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy